Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aclaris Therapeutics (ACRS) Change in Account Payables (2017 - 2025)

Historic Change in Account Payables for Aclaris Therapeutics (ACRS) over the last 9 years, with Q3 2025 value amounting to $377000.0.

  • Aclaris Therapeutics' Change in Account Payables fell 407.12% to $377000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.5 million, marking a year-over-year increase of 19391.3%. This contributed to the annual value of -$4.2 million for FY2024, which is 18431.77% down from last year.
  • Aclaris Therapeutics' Change in Account Payables amounted to $377000.0 in Q3 2025, which was down 407.12% from $2.4 million recorded in Q2 2025.
  • In the past 5 years, Aclaris Therapeutics' Change in Account Payables ranged from a high of $3.2 million in Q2 2023 and a low of -$3.5 million during Q2 2024
  • In the last 5 years, Aclaris Therapeutics' Change in Account Payables had a median value of $393000.0 in 2024 and averaged $149789.5.
  • Its Change in Account Payables has fluctuated over the past 5 years, first soared by 93144.1% in 2021, then plummeted by 65431.47% in 2024.
  • Over the past 5 years, Aclaris Therapeutics' Change in Account Payables (Quarter) stood at $2.4 million in 2021, then grew by 13.76% to $2.7 million in 2022, then tumbled by 114.66% to -$394000.0 in 2023, then tumbled by 654.31% to -$3.0 million in 2024, then skyrocketed by 112.69% to $377000.0 in 2025.
  • Its Change in Account Payables stands at $377000.0 for Q3 2025, versus $2.4 million for Q2 2025 and $1.7 million for Q1 2025.